Satralizumab
- Generic Name
- Satralizumab
- Brand Names
- Enspryng
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1535963-91-7
- Unique Ingredient Identifier
- YB18NF020M
- Background
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the cent...
- Indication
Satralizumab is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In Canada, it is also used in adolescent patients for the same indication.
- Associated Conditions
- Neuromyelitis Optica Spectrum Disorders
- Associated Therapies
- -
An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06450639
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny w Poznaniu; Od. Kliniczny Neurologii Dzieci i Młodzieży, Poznań, Poland
🇵🇱Instytut Centrum Zdrowia Matki Polki; Klinika Neurologii Rozwojowej i Epileptologii, Łódź, Poland
🇺🇸Child(ren's) Hosp(ital) of the king's daughters, Norfolk, Virginia, United States
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT06106828
- Locations
- 🇨🇦
Serac Eye and Skin Care Centre, Calgary, Alberta, Canada
🇺🇸Plastics-Orbit-Neuro, San Diego, California, United States
🇺🇸Eye Care Center of Northern Colorado PC, Longmont, Colorado, United States
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT05987423
- Locations
- 🇺🇸
Eye Associates of New Mexico, Tucumcari, New Mexico, United States
🇺🇸'Northwell Health Physician Partners Ophthalmology, Great Neck, New York, United States
🇺🇸Thrive Health Research LLC, Beverly Hills, California, United States
Satralizumab in Aneurysmal Subarachnoid Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Florida
- Registration Number
- NCT05727657
- Locations
- 🇺🇸
University of Florida (UF) Health Shands Hospital, Gainesville, Florida, United States
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT05503264
- Locations
- 🇫🇷
Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris, France
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸UC San Diego; ACTRI, La Jolla, California, United States
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
- Conditions
- Interventions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT05271409
- Locations
- 🇦🇺
Royal Childrens Hospital; Childrens Neuroscience Centre, Parkville, Victoria, Australia
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic- Scottsdale, Scottsdale, Arizona, United States
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT05199688
- Locations
- 🇵🇱
Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇫🇷Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-bicêtre, France
🇦🇷Clinica Universitaria Reina Fabiola, Cordoba, Argentina
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 188
- Registration Number
- NCT04963270
- Locations
- 🇺🇸
Keck School of Medicine of USC, Los Angeles, California, United States
🇺🇸SC3 Research Group, Inc, Pasadena, California, United States
🇺🇸Childrens National Health Center, Washington, District of Columbia, United States
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT04660539
- Locations
- 🇺🇸
Jefferson Hospital For Neuroscience; Jefferson Neurology Associates, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 95
- Registration Number
- NCT02073279
- Locations
- 🇺🇸
University of Colorado Denver -; Neurology, Aurora, Colorado, United States
🇺🇸University of Miami UHealth Professional Arts Center, Miami, Florida, United States
🇺🇸Columbus Research and Wellness, Columbus, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.